PulseTech delivers Startup Bangladesh’s first multi-fold return after revenue surge

In young startup ecosystems, the first meaningful return matters almost as much as the cheque that produced it. It gives founders, investors and policymakers something more concrete than optimism: proof that local companies can grow fast, make money, and return capital.

Bangladesh has now reached one of those moments. Startup Bangladesh, the government-backed venture capital fund under the country’s ICT Division, has secured its first multi-fold investment return from PulseTech, a Dhaka-based pharmaceutical distribution startup that has grown from US$2 million to US$150 million in annualised revenue in two years.

Also Read: Why money won’t save Bangladesh’s startups: The ecosystem readiness crisis

The fund first invested in PulseTech in 2024. It has not disclosed the size of the original investment, the return multiple, or whether the transaction was a partial or full exit. Still, the development is notable for a market where venture-backed exits remain limited and where much of the startup narrative has, until recently, centred on funding access rather than capital recycling.

Startup Bangladesh was set up as a catalytic public venture fund to back technology companies solving local problems. It has invested in 36 startups since inception. For a government-sponsored vehicle, the PulseTech outcome is more than a portfolio update; it is a test case for whether public capital can help de-risk early companies and then draw in later private investors.

“At Startup Bangladesh, we invest with a purpose — to empower entrepreneurs solving real-world challenges while creating sustainable economic and social impact,” said Nurul Hai, MD and CEO of Startup Bangladesh. He added that the milestone “validates our catalytic investment approach” and reinforces the fund’s commitment to backing globally competitive Bangladeshi startups.

Fixing a fragmented medicine supply chain

PulseTech operates in a sector that is essential, large and messy. Bangladesh’s pharmaceutical market is worth about US$6 billion, according to the Bangladesh Investment Development Authority, but distribution remains fragmented. Independent pharmacies often buy from multiple suppliers or wholesale markets, creating inefficiencies in pricing, availability and delivery.

The bigger risk is trust. Fragmented supply chains can make it easier for counterfeit or substandard medicines to enter the market, especially when small retailers lack direct access to reliable distributors. This problem is familiar across many emerging Asian markets, including parts of Southeast Asia, where neighbourhood pharmacies still form a critical layer of healthcare access but often operate with limited technology and working capital.

PulseTech’s answer is MedBox, an app-based ordering and delivery network that allows small pharmacies to source authentic medicines through a licensed pharmaceutical distributor and receive same-day delivery. The company has layered additional services on top of this base, including embedded financing, pharmacy software and ONE Pharmacy, a franchise network that brings independent retailers under a shared brand.

That model gives PulseTech multiple ways to deepen its relationship with pharmacies. Distribution solves procurement. Software can help retailers manage stock and sales. Financing can give small operators the cash flow to buy inventory. Franchising, if executed well, can standardise parts of the retail experience without forcing independent owners to give up their businesses.

Since Startup Bangladesh’s initial investment, the company says it has maintained profitability while growing revenue at an average month-on-month rate of 20 per cent. It now serves more than 14,000 retail pharmacies in Dhaka, collectively reaching over 8.5 million people with what it describes as authentic, counterfeit-free medicines.

Also Read: Bangladesh’s startup ecosystem is entering a new phase of investability

Those figures are large for a young company, but they also point to how much work remains. PulseTech says it currently serves less than 5 per cent of Bangladesh’s pharmaceutical market. In other words, the company has built early scale without yet touching most of the opportunity.

A signal for Bangladesh and nearby markets

For Southeast Asian founders and investors, the PulseTech story will feel familiar in some respects. Across Indonesia, Vietnam, the Philippines and other markets, much of the startup opportunity lies not in inventing entirely new consumer behaviour, but in digitising the informal or semi-formal systems that already move goods, credit, healthcare and services.

Pharmacy distribution fits that pattern. It is not a glamorous category, but it is high-frequency, operationally complex and deeply local. Companies that succeed need more than an app; they need warehousing, delivery discipline, regulatory compliance, supplier relationships and trust from small merchants who may have run their businesses the same way for decades.

That makes PulseTech’s profitability claim important. In the past few years, investors across Southeast Asia and South Asia have become more sceptical of growth built on subsidies. B2B commerce companies, in particular, have faced hard questions about margins, working capital and retention once incentives fade. A pharma distribution platform that can grow quickly while staying profitable will attract attention, especially if it proves its model beyond Dhaka.

PulseTech is now raising a Series A round as it targets US$1 billion in revenue. It also plans to enter Saudi Arabia as its first international market beyond Bangladesh. The choice is ambitious. Saudi Arabia has a far larger healthcare market, stronger purchasing power and an active digital transformation agenda, but it also has established pharmacy chains, distributors and regulators with their own requirements.

Arefeen Raafi Ahmed, co-founder and Managing Director of PulseTech, said Startup Bangladesh’s early backing played a role in the company’s growth. “This successful investment return shows that Bangladesh has the talent and ecosystem to build and scale companies capable of generating meaningful returns for investors,” he said.

The competitive map

PulseTech is not building in a vacuum. In Southeast Asia, Singapore-headquartered SwipeRx has spent years digitising pharmacies and connecting them with suppliers across markets such as Indonesia, the Philippines and Vietnam. In India, platforms including Retailio and Pharmarack have targeted medicine procurement and distribution for pharmacies, while large players such as Tata 1mg and PharmEasy operate in adjacent digital health and pharmacy commerce segments. Globally, pharmaceutical distribution is dominated by giants such as McKesson, Cencora and Cardinal Health in the US, while Gulf markets have their own entrenched distributors and pharmacy groups. PulseTech’s edge, if it sustains one, will come from execution in under-digitised pharmacy networks and its ability to bundle distribution, software, financing and retail branding in markets where independent pharmacies still matter.

The company’s next phase will test whether that bundle travels. Bangladesh offers the advantage of familiarity: local relationships, market knowledge and a clear pain point. International expansion, particularly to the Middle East, requires a different playbook. Regulatory approvals, product sourcing, insurance systems and pharmacy ownership rules vary sharply between markets.

There is also the question of capital discipline. Scaling distribution businesses can consume cash quickly because inventory, logistics and credit all need funding. Embedded financing can increase customer stickiness, but it also brings credit risk. Franchise networks can build brand power, but they require operational consistency. PulseTech’s ability to manage those moving parts may determine whether it becomes a regional healthcare infrastructure company or remains a strong domestic distributor.

Still, for now, the return to Startup Bangladesh gives the ecosystem a tangible win. Frontier startup markets often need examples before they get flywheels: one return encourages more risk-taking, brings in new investors, and gives founders a clearer path from early backing to later capital.

Also Read: 20 game-changing startups driving Bangladesh’s innovation wave

Kazi Ashikur Rasul, co-founder and CEO of PulseTech, framed the outcome as proof that commercial and social goals need not be at odds. “Over the past two years, we’ve expanded access to authentic medicines for millions of people while building a profitable, fast-growing company,” he said.

That is the central claim PulseTech now has to prove at a larger scale. If it can, Bangladesh may have more than its first multi-fold venture return. It may have a blueprint for building exportable technology companies from overlooked but essential sectors.

The post PulseTech delivers Startup Bangladesh’s first multi-fold return after revenue surge appeared first on e27.